SLC5A5 and prostate cancer: Prostate cancer has been targeted for NIS gene therapy in numerous pre-clinical studies.29 Using adenovirus as a vector, NIS gene expression in prostate tissue has, in a Phase 1 trial, proven the 99mTc-imaging approach to be both safe and feasible.30 Further study is ongoing.31 To date, no human trials have studied the potential of oncolytic viral therapy to additionally enable NIS 131I therapy.